Compare ATRC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | HROW |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2005 | N/A |
| Metric | ATRC | HROW |
|---|---|---|
| Price | $41.22 | $46.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $52.00 | ★ $68.86 |
| AVG Volume (30 Days) | ★ 572.3K | 535.4K |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $518,304,999.00 | $250,042,000.00 |
| Revenue This Year | $16.90 | $39.05 |
| Revenue Next Year | $12.29 | $40.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 15.80 | ★ 47.83 |
| 52 Week Low | $28.29 | $20.85 |
| 52 Week High | $43.11 | $51.30 |
| Indicator | ATRC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 57.53 |
| Support Level | $38.92 | $44.48 |
| Resistance Level | $42.42 | $51.30 |
| Average True Range (ATR) | 1.66 | 2.48 |
| MACD | 0.56 | 0.51 |
| Stochastic Oscillator | 83.07 | 59.44 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.